José Miguel Lizcano

This study shows that inhibiting ERK5 causes CDK6 degradation and enhances palbociclib's effectiveness in melanoma and endometrial cancer cells.

This paper identifies ERK5 as a regulator of MHC-I expression in cancer cells, showing that inhibiting ERK5 increases MHC-I levels and enhances CD8+ T cell-mediated apoptosis.

This study shows TRIB3 silencing reduces Akt pathway activity and PAX3-FOXO1 levels in high-risk rhabdomyosarcoma, leading to decreased tumor growth and improved survival.

This study identifies an ERK5-KLF2 signalling module that regulates 2C gene expression and mESC rejuvenation through both transcriptional activation and phosphorylation-induced degradation of KLF2.